Compare RGS & ACET Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RGS | ACET |
|---|---|---|
| Founded | 1922 | 1947 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 72.0M | 77.3M |
| IPO Year | 1994 | 2017 |
| Metric | RGS | ACET |
|---|---|---|
| Price | $29.50 | $9.38 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $48.33 |
| AVG Volume (30 Days) | 7.7K | ★ 92.0K |
| Earning Date | 05-06-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 20.24 | N/A |
| EPS | ★ 0.89 | N/A |
| Revenue | ★ $210,134,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $32.87 | ★ N/A |
| Revenue Growth | ★ 3.52 | N/A |
| 52 Week Low | $18.23 | $0.46 |
| 52 Week High | $31.50 | $9.05 |
| Indicator | RGS | ACET |
|---|---|---|
| Relative Strength Index (RSI) | 54.47 | 67.27 |
| Support Level | $25.95 | $7.36 |
| Resistance Level | $28.51 | N/A |
| Average True Range (ATR) | 1.06 | 0.58 |
| MACD | 0.00 | 0.10 |
| Stochastic Oscillator | 64.91 | 96.08 |
Regis Corporation owns, franchises, and operates beauty salons in North America and the U.K., serving mainly price-conscious customers. Its salons, located mostly in strip malls, shopping centers, and Walmart stores, offer services like haircutting, styling, shampooing, conditioning, and hair coloring, along with hair care and beauty products. The company's primary brands include Supercuts, SmartStyle, and Cost Cutters. Regis generates the majority of its revenue from these mass-market locations and reports operations in two segments: franchise and company-owned, with services making up about 94% of company-owned salon sales.
Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. It is advancing a pipeline of off-the-shelf gamma delta T cells, engineered with chimeric antigen receptors (CARs), to facilitate durable activity in patients. The company's main product candidate, prulacabtagene leucel (prula-cel), is an allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, and is being developed for the potential treatment of autoimmune diseases. Additionally, it is pursuing ADI-212, a next-generation gene-edited and armored clinical candidate designed to target prostate-specific membrane antigen (PSMA).